Bajaj Healthcare Q3 PAT up 34% YoY at Rs 15.67 cr; board re-appoints 4 directors
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bajaj Healthcare reported Q3 FY26 revenue of Rs 161.22 cr, up 31% YoY from Rs 122.79 cr. Total PAT rose 34% to Rs 15.67 cr vs Rs 11.72 cr. For 9M FY26, revenue grew 18% to Rs 457.97 cr while total PAT grew 36% to Rs 38.62 cr. Discontinued operations narrowed losses. The board also approved re-appointment of four executive directors for three-year terms and issued a postal ballot notice.
Strong Q3 with revenue and PAT both growing over 30% YoY; director re-appointments signal continuity. Positive for shareholders.